AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

LYRA(Quitar la ciudad)

Lyra Therapeutics·NASDAQ
--
--(--)

Lyra Therapeutics (LYRA) Stock Statistics, Valuation & Financial Metrics

Total Valuation

Lyra Therapeutics market cap is -- and enterprise value is --.

Share Statistics

Lyra Therapeutics has 1.77M shares outstanding, with a free float of 1.63M.

Valuation Ratios

Lyra Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.

Solvency

Lyra Therapeutics debt-to-equity ratio is 0 and debt-to-assets ratio is 1.1.

Liquidity

Lyra Therapeutics's current ratio is 2.43, quick ratio is 2.43, and cash ratio is 2.33, showing its short-term liquidity position.

Return on Capital

Lyra Therapeutics's ROE is -404.48%, ROA is -53.81%, and ROIC is -433.70%, showing its return on capital profile.

ROE (TTM)
-404.48%
ROIC (TTM)
-433.70%
ROA (TTM)
-53.81%

Profitability

Lyra Therapeutics gross margin is 100.00%, operating margin is -5885.33%, and net margin is -5491.17%.

Cost Structure

Lyra Therapeutics spends 3399.17% of revenue on R&D and 2102.17% on SG&A.

Operating Efficiency

Lyra Therapeutics's asset turnover is 0.01, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.

Revenue Per Employee
51.13K
Profits Per Employee
-3.11M

Income Statement

Lyra Therapeutics's revenue is 770.00K, gross profit is 600.00K, net income is -38.84M, and EBITDA is -41.07M.

Basic EPS (TTM) YoY Growth
+69.24%
Revenue (TTM) YoY Growth
-59.21%
EBIT (TTM)
-41.52M

Balance Sheet

Lyra Therapeutics's total debt is 0, net debt is 0, total equity is -4.33M, and cash is 22.05M.

Cash Flow Statement

Lyra Therapeutics's operating cash flow is -34.15M, free cash flow is -34.11M, and CapEx is 38.00K.

Dividends & Yields

Lyra Therapeutics dividend yield is --, with a payout ratio of 0.00% and dividend per share of --.

Analyst Rating

Lyra Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.

Analyst Rating
Unrate

Company Info

A clinical-stage therapeutics company offering a platform that enable precise, sustained and local delivery of medications to the ear, nose and throat passages and other diseased tissues

Listing Date
2020-05-01
Employees
30

Per Share Metrics

Lyra Therapeutics's EPS is -22.9, book value per share is -2.63, and free cash flow per share is --.